Company Description
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease.
The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation.
Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee’s Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate.
The company was incorporated in 2016 and is based in Los Altos, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Shalabh Gupta |
Contact Details
Address: 4300 El Camino Real, Suite 210 Los Altos, California 94022 United States | |
| Phone | 650 351 4495 |
| Website | unicycive.com |
Stock Details
| Ticker Symbol | UNCY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001766140 |
| CUSIP Number | 90466Y103 |
| ISIN Number | US90466Y1038 |
| Employer ID | 81-3638692 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, Chief Executive Officer and President |
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Operations |
| Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
| John W. Townsend CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 424B5 | Filing |
| Jun 10, 2025 | 8-K | Current Report |
| Jun 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 9, 2025 | 8-K | Current Report |
| May 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 21, 2025 | 8-K | Current Report |